FONT-SIZE Plus   Neg

Shire's DERMAGRAFT Approved In Canada For Treating Diabetic Foot Ulcers

Shire Plc (SHP.L, SHPG) said its lead regenerative medicine product, DERMAGRAFT (human fibroblast-derived dermal substitute) secured regulatory approval from Health Canada as a class IV medical device for the treatment of diabetic foot ulcers (DFUs), a complication of diabetes.

Shire Regenerative Medicine plans to make DERMAGRAFT available in Canada in the first quarter of 2013, and will leverage Shire's current infrastructure and commercial knowledge of the Canadian healthcare system.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Microsoft's (MSFT) office assistant Cortana for iOS beta has arrived, but only 2000 people will be able to test the virtual assistant. Apple confirmed that it has bought face animation software firm Faceshift, although it was tight lipped about how it intends to use the new addition. The move is speculated as a bid to expand into virtual reality. Environment ministry of South Korea Thursday ordered Volkswagen Korea to recall 125,522 diesel vehicles on determining actual emissions of nitrogen oxides. The ministry has asked the German automobile maker to pay a fine of 14.1 billion Won or $12.31 million. The company has to submit a recall plan by January 6, 2016.
comments powered by Disqus
Follow RTT